Global Dopamine Agonist Drug Market, By Type (Non-Ergoline Dopamine Agonists, Ergot-Derived Dopamine Agonists, Recombinant Factor VIII and Others), Indication (Parkinson's Disease, Restless Leg Syndrome and Others), Drugs (Carbidopa and Levodopa, Ropinirole, Pramipexole, Cabergoline, Bromocriptine and Others), Route of Administration (Oral, Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
The dopamine agonist drug market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with the CAGR of 4.8% in the forecast period of 2021 to 2028.
Dopamine agonists are a class of drugs that activates postsynaptic dopamine receptors directly into the brain. It is generally used to treat the symptoms of Parkinson’s disease (PD). It basically works by reducing the motor fluctuations in the individual suffering from Parkinson’s disease.
Increase in special designation from the regulatory authorities and ongoing clinical trial conducted by many pharmaceuticals industries are further expected to accelerate the overall growth of the dopamine agonist drug market within the forecast period. Additionally, high demand of disease specific novel treatment also boost the market’s growth. However, low healthcare budget in some developing countries , patent expiration of branded drugs, and introduction of generics are the factors anticipated to most likely obstruct the growth of the dopamine agonist drug market in the coming years.
Additionally, the competitive scenario of market and strategic collaborations are to further extend suitable opportunities for the growth of the dopamine agonist drug market in the near future. However, the limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals might impede the market’s growth which can be one of the challenging factor within the forecast period.
This dopamine agonist drug market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on dopamine agonist drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Dopamine Agonist Drug Market Scope and Market Size
The dopamine agonist drug market is segmented on the basis of type, indication, drugs, route of administration, end- users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- Based on the type, the dopamine agonist drug market is segmented into non-ergoline dopamine agonists, ergot-derived dopamine agonists, recombinant factor VIII and others.
- On the basis of indication, the market is bifurcated into parkinson's disease, restless leg syndrome and others.
- On the basis of drugs, the dopamine agonist drug market is segmented into carbidopa and levodopa, ropinirole, pramipexole, cabergoline, bromocriptine and others.
- On the basis of route of administration, the market is segmented into oral and injectable.
- On the basis of end- users, the dopamine agonist drug market is segmented into hospitals, homecare, specialty clinics, and others
- On the basis of distribution channel, the market is segmented into hospital pharmacies and retail pharmacies.
Dopamine Agonist Drug Market Country Level Analysis
The dopamine agonist drug market is analyzed and market size insights and trends are provided by type, indication, drugs, route of administration, end- users and distribution channel as referenced above.
The countries covered in the dopamine agonist drug market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the dopamine agonist drug market due to the availability of advanced treatment and well-developed healthcare infrastructure within the region. On the other hand, Asia Pacific is projected to observe significant amount of growth in the dopamine agonist drug market owing to the steady development healthcare infrastructure and increasing government investments in the research and development and for spreading awareness regarding advanced treatment modalities.
The country section of the dopamine agonist drug market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Dopamine Agonist Drug Market Share Analysis
The dopamine agonist drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to dopamine agonist drug market.
The major players covered in the dopamine agonist drug market report are GlaxoSmithKline plc, Intas Pharmaceuticals Ltd, Amarin Corporation, Acorda Therapeutics, Inc, USWM, LLC, Kirin Holdings Company, Limited, UCB S.A., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, intecpharma, Merck & Co., Inc, Novartis AG, Serina Therapeutics, Apotex Inc, Teva Pharmaceutical Industries Ltd, Mylan N.V., Glenmark Pharmaceuticals Ltd, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd among others domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.